Cyxone focuses on developing drugs for autoimmune diseases
Cyxone AB is a Swedish biotech company founded in 2015 with the aim of developing drugs with cyclotide technology that can considerably improve quality of life for people living with severe autoimmune diseases. The company is run via an international network of different experts within research, development and manufacturing, including the scientific founders in Austria and Germany. The driving force is to develop a strong drug portfolio with innovative and effective treatment methods to decrease the side effects and slow down the disease development in order to improve quality of life for people affected by severe immune-related disorders. Cyxone’s portfolio is based on a solid research platform with a type of biological molecules that have proven to work well as a drug for humans. The company’s development portfolio comprises Rabeximod in clinical phase II program for rheumatoid arthritis (RA) and T20K that soon will be in clinical phase I for multiple sclerosis (MS). In future, Cyxone will also use its cyclotide technology to develop new structures that may prove beneficial for patients in other disease areas.